logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden : cost effectiveness analysis.

    Article - En anglais

    Objective 

    To analyse the cost effectiveness of a national programme to screen blood donors for infection with the human T cell leukaemia/lymphoma virus.

    Design 

    Three models for calculating the costs and benefits of screening were developed.

    The first model analysed the cost of continuously testing all donations ; the second analysed the cost of initially testing new blood donors and then retesting them after five years ; the third analysed the cost of testing donors only at the time of their first donation.

    Patients who had received blood components from donors confirmed to be infected with the virus were offered testing.

    Setting 

    Sweden.

    Main outcome measures 

    Prevalence of infection with the virus among blood donors, the risk of transmission of the virus, screening costs, and the outcome of infection.

    Results 

    648 497 donations were tested for the virus ; 1625 samples tested positive by enzyme linked immunosorbent assay. 6 were confirmed positive by western blotting.

    The prevalence of infection with the virus was 2/100 000 donors. 35 patients who had received blood infected with the virus were tested ; 3 were positive.

    The cost of testing every donation was calculated to be $3.02m (£1.88m) ; this is 18 times higher than the cost of testing new donors only, and only 1 additional positive donor would be discovered in 7 years.

    Regardless of the model used, screening was estimated to prevent only 1 death every 200 years at a minimum cost of $36m (£22.5m). (...)

    Mots-clés Pascal : Virus HTLV, Retroviridae, Virus, Virose, Infection, Don sang, Donneur sang, Dépistage, Diagnostic, Analyse coût efficacité, Homme, Economie santé, Suède, Europe, Transfusion

    Mots-clés Pascal anglais : HTLV virus, Retroviridae, Virus, Viral disease, Infection, Blood donation, Blood donor, Medical screening, Diagnosis, Cost efficiency analysis, Human, Health economy, Sweden, Europe, Transfusion

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0262101

    Code Inist : 002B05C02E. Création : 11/09/1998.